Peer-Review Record
Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo
Int. J. Mol. Sci. 2021, 22(21), 11936; https://doi.org/10.3390/ijms222111936
by
Dimitrios Vagiannis 1
, Youssif Budagaga 1, Anselm Morell 2, Yu Zhang 1, Eva Novotná 2, Adam Skarka 3, Sarah Kammerer 4, Jan-Heiner Küpper 4, Ivo Hanke 5, Tomáš Rozkoš 6 and Jakub Hofman 1,*
, Youssif Budagaga 1, Anselm Morell 2, Yu Zhang 1, Eva Novotná 2, Adam Skarka 3, Sarah Kammerer 4, Jan-Heiner Küpper 4, Ivo Hanke 5, Tomáš Rozkoš 6 and Jakub Hofman 1,*Reviewer 1:
Anonymous
Reviewer 2:
Anonymous
Int. J. Mol. Sci. 2021, 22(21), 11936; https://doi.org/10.3390/ijms222111936
Submission received: 8 October 2021
/
Revised: 27 October 2021
/
Accepted: 28 October 2021
/
Published: 3 November 2021
(This article belongs to the Collection Feature Papers in Molecular Pharmacology)
Round 1
Reviewer 1 Report
In this paper by Dr. Vagiannis et al., the authors describe the characterization of the effect of tepotinib on the ABCB2 and ABCG2 efflux transporters by the use of molecular biological and biochemical experiments.
The study is clinically relevant, the experiments are well designed and well described. I have no constructive criticism to the manuscript.
Author Response
Please see the attachment.
Reviewer 2 Report
Good study. Need to include more details in the methods sections, even though they have published previously. Also, controls should be included in all figures not some.
Author Response
Please see the attachment.
Author Response File: 
Author Response.pdf
